BioPorto Diagnostics


DKK1395m market cap

DKK5.21 last close

BioPorto Diagnostics is a diagnostic company focused on the development and commercialisation of biomarker-based assays. The company’s portfolio includes The NGAL Test, for the prediction of acute kidney injury, and an extensive antibody library.

Investment summary

BioPorto managed to continue sales growth for its NGAL research-use only (RUO) product in 2020 despite the headwinds of COVID-19. Sales of the product increased 28% over the prior year (DKK13.4m from DKK10.5m) despite the disruption. We are encouraged to see this growth as we expect physicians with exposure to the test to become the first customers after the launch of the approved NGAL Test for clinical use.

Y/E Dec
Revenue (DKKm)
EPS (ore)
P/E (x)
P/CF (x)
2019A 26.6 (68.3) (71.1) (39.16) N/A N/A
2020A 23.2 (54.3) (61.5) (28.10) N/A N/A
2021E 32.2 (71.4) (74.9) (25.33) N/A N/A
2022E 179.3 68.3 64.5 20.79 25.1 N/A
Industry outlook

The current standard of care for detecting AKI is serum creatinine, which can take 24 hours or more to detect AKI and can only do so after significant kidney damage. NGAL promises to provide a quicker and more reliable test, allowing early intervention to preserve kidney function.

Last updated on 13/04/2021
Register to receive research on BioPorto Diagnostics as it is published
Share price graph
Balance sheet
Forecast net cash (DKKm) 46.4
Forecast gearing ratio (%) N/A
Price performance
Actual (11.1) (9.2) 111.7
Relative* (15.2) (12.0) 50.8
52-week high/low DKK7.8/DKK1.9
*% relative to local index
Key management
Thomas Magnussen Chairman
Peter Mørch Eriksen CEO
Ole Larsen CFO
Jan Kuhlmann Andersen COO

Content on BioPorto Diagnostics